Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension.
about
Inflammatory cytokines in pulmonary hypertensionMetabolic dysfunction in pulmonary hypertension: the expanding relevance of the Warburg effectInflammation and immunity in the pathogenesis of pulmonary arterial hypertensionMechanisms of NFATc3 activation by increased superoxide and reduced hydrogen peroxide in pulmonary arterial smooth muscle.Exercise-induced AMPK and pyruvate dehydrogenase regulation is maintained during short-term low-grade inflammationBMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertensionProfiling the role of mammalian target of rapamycin in the vascular smooth muscle metabolome in pulmonary arterial hypertension.Endothelial uncoupling protein 2 regulates mitophagy and pulmonary hypertension during intermittent hypoxiaAn inhibitory effect of tumor necrosis factor-alpha antagonist to gene expression in monocrotaline-induced pulmonary hypertensive rats model.NFAT is required for spontaneous pulmonary hypertension in superoxide dismutase 1 knockout mice.Intratracheal instillation of ethyl pyruvate nanoparticles prevents the development of shunt-flow-induced pulmonary arterial hypertension in a rat model.Pulmonary arterial hypertension: challenges in translational research and a vision for change.Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety.The role of nuclear factor of activated T cells in pulmonary arterial hypertension.Altered Redox Balance in the Development of Chronic Hypoxia-induced Pulmonary Hypertension.Pentose Shunt, Glucose-6-Phosphate Dehydrogenase, NADPH Redox, and Stem Cells in Pulmonary Hypertension.Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension.Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients.FoxO1 regulates myocardial glucose oxidation rates via transcriptional control of pyruvate dehydrogenase kinase 4 expression.Downregulation of Kv1.5 K channels by the AMP-activated protein kinase.Immune regulation of systemic hypertension, pulmonary arterial hypertension, and preeclampsia: shared disease mechanisms and translational opportunities.Angiotensin-(1-9) ameliorates pulmonary arterial hypertension via angiotensin type II receptor.Therapeutic hypercapnia prevents bleomycin-induced pulmonary hypertension in neonatal rats by limiting macrophage-derived tumor necrosis factor-α
P2860
Q27007510-D78457E5-2578-4B9B-AEF1-8231DCEB07D5Q27024293-5E11162C-048A-45AC-95BE-A00D0E0433CAQ33898213-12630278-BC25-4B84-AA21-6B850E3B6E48Q34519078-682E045F-F635-4A9B-BC81-24170D6256E3Q34947306-6EC148FA-2759-40FC-86A9-20F278EA9D4EQ35376926-9F5892E7-AFF2-432E-9139-69EA7195E3E3Q36352098-F621DE1E-C5FA-4EFC-8160-3887E663C84BQ36490033-34EA0953-1DBF-4AF8-9E80-A85ABDA38F6CQ36725312-9CECADF7-52E3-4AB3-A63D-996D709C2832Q36837739-ACA3CAE8-8564-428F-A918-F24AC0039ACEQ37003895-D7D1F46E-84AA-42B1-AB41-55D1A90D32FBQ38155079-11B855C8-171D-48EA-BB4D-F4F7F6066A8EQ38175430-2C1769D9-1E21-44E1-89B8-A18981F9CA20Q39095141-1D20AEC0-1E6E-4B6A-84F3-842AA4669E10Q46280877-06B2A7F3-B048-4DD5-9581-DD642292BEC6Q46280894-B12E4ED7-9DC4-4058-B83B-A873F991EA9DQ47130813-317AF5EB-3653-4C1E-A8AD-0BB77669F169Q47410087-7782F40E-39D6-4C2E-A45A-93AFAA7312D6Q47834016-FC2CD0BC-DC70-4476-B3E4-554671B6C99EQ48634800-932C02D7-D761-4315-9365-C4E38C414115Q49600503-874E13ED-15BA-4B2A-BFA8-9CC12302A67CQ55360608-17828468-5003-42D2-A4A6-1FF9BFD86246Q59161635-F6862A4F-F8F6-4560-92A5-BE6A645CE1F2
P2860
Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Pyruvate dehydrogenase inhibit ...... lmonary arterial hypertension.
@en
Pyruvate dehydrogenase inhibit ...... lmonary arterial hypertension.
@nl
type
label
Pyruvate dehydrogenase inhibit ...... lmonary arterial hypertension.
@en
Pyruvate dehydrogenase inhibit ...... lmonary arterial hypertension.
@nl
prefLabel
Pyruvate dehydrogenase inhibit ...... lmonary arterial hypertension.
@en
Pyruvate dehydrogenase inhibit ...... lmonary arterial hypertension.
@nl
P2093
P2860
P1476
Pyruvate dehydrogenase inhibit ...... lmonary arterial hypertension.
@en
P2093
Alois Haromy
Evangelos D Michelakis
Gopinath Sutendra
Michael S McMurtry
Peter Dromparis
R Chris Bleackley
Sébastien Bonnet
P2860
P2888
P304
P356
10.1007/S00109-011-0762-2
P577
2011-08-02T00:00:00Z